U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator

Government Agency Acknowledges Innovative Breast Cancer Diagnostic Imaging Tool

Mar 31, 2011, 08:00 ET from Dilon Diagnostics

NEWPORT NEWS, Va., March 31, 2011 /PRNewswire/ -- The U.S. Department of Energy has acclaimed Dilon Diagnostics as a success story in the field of medical technology and innovation for commercializing the technologies of the national laboratories. According to the government agency, Dilon and similar entrepreneurs, "build the new industries of the 21st century, and help solve some of our toughest global challenges."

The Dilon 6800® digital gamma camera is based on gamma-imaging technology developed at the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility in Newport News, Va. The medical procedure that this advanced imaging technology enables is known as Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI), and reveals cancerous lesions even at very early stages. BSGI/MBI is a proven technology that can find cancers missed by mammography and ultrasound.

"We are honored to be acknowledged by the Department of Energy as one the country's successful innovators in the medical technology field," said Bob Moussa, President and CEO of Dilon. "We have been able to make a significant impact by utilizing our licensing agreement with Jefferson Lab to help save lives."

Dilon sells its products across Europe, Asia, and the U.S., and recently signed on distributors in Mexico, Australia and Russia Many leading medical centers around the country are now offering BSGI/MBI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. More than 250,000 patients have been screened with BSGI/MBI on a worldwide basis.

About BSGI/MBI

As a follow-up to mammography, BSGI/MBI utilizes the Dilon 6800® Gamma Camera to help physicians see the breast more clearly and differentiate benign from malignant tissue. To perform BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as dark spots on the BSGI image.

BSGI/MBI is especially valuable after a questionable mammogram. This can occur when patients have dense breast tissue; implants; multiple suspicious lesions or clusters of microcalcifications; palpable lesions that can be felt but not detected by mammography or ultrasound; post-surgical or post-therapeutic mass; or if they have been taking hormone replacement therapy.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view digital gamma camera. It is optimized to perform BSGI, a molecular breast imaging procedure that images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.

About "America's Next Top Energy Innovator"

For more information, please visit http://www.energy.gov/news/10202.htm

SOURCE Dilon Diagnostics



RELATED LINKS

http://www.dilon.com